GlobalData on MSN
Tandem secures FDA approval for Control-IQ+ use in pregnancy
The approval is based on findings from the CIRCUIT trial published in JAMA in October 2025.
SAN DIEGO--(BUSINESS WIRE)--Tandem Diabetes Care, Inc. (Nasdaq: TNDM) and Dexcom, Inc. (Nasdaq: DXCM), today announced that the Tandem Mobi insulin pump with Control-IQ technology is now fully ...
– Enhanced features extend automated insulin delivery (AID) to people ages 2 years and older with type 1 diabetes and adults with type 2 diabetes – Control-IQ+ automated insulin delivery technology ...
FDA clears Tandem Diabetes Care's Control-IQ+ automated insulin delivery technology for use in pregnancy for people with type ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results